Alexion Pharmaceuticals, Inc. AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, October 26 to 28, 2022. Data presented at the meeting will feature new insights from Alexion's complement portfolio illustrating the critical role of C5 inhibition in treating AQP4 Ab+ NMOSD and significantly reducing the risk of relapses, including findings on the first and only long-acting C5 complement inhibitor, ULTOMIRIS® (ravulizumab-cwvz). Redefining NMOSD disease management; An oral presentation will showcase results of the CHAMPION-NMOSD trial, which evaluated the safety and efficacy of ULTOMIRIS in adults with AQP4 Ab+ NMOSD, compared to the external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial.

The data will show there were zero adjudicated on-trial relapses observed in patients with AQP4 Ab+ NMOSD with a median treatment duration of 73 weeks, representing a relapse risk reduction of 98.6% (p<0.0001) compared to the external placebo arm. The safety and tolerability of ULTOMIRIS in the CHAMPION-NMOSD trial were consistent with previous clinical studies and other approved indications. Improving understanding of the NMOSD patient experience; Two poster presentations detail findings from qualitative interviews with NMOSD patients.

This work helps to inform the scientific community about the immediate and lasting impact of relapses, including ability to work and participate in daily activities, mobility and pain as well as reliance on caregiver support. What is ULTOMIRIS? ULTOMIRIS is a prescription medicine used to treat: adults and children 1 month of age and older with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).

adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS). ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age. It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children. Subcutaneous administration of ULTOMIRIS has not been evaluated and is not approved for use in children.